In the total population, our findings are compatible with a previous meta-analysis [12] showing the beneficial role of the AIP in predicting MAFLD or NAFLD with internal validation and secondary validation showing an AUC > 0.7. This evidence concerns the gene AIP and metabolic dysfunction-associated steatotic liver disease.